|
|
含贝达喹啉方案治疗MDR/RR-TB的安全性应用研究进展
|
Abstract:
贝达喹啉(Bendaquinoline, Bdq)是一种二芳基喹啉类抗结核药物，主要用于治疗耐多药结核病(MDR-TB)或利福平耐药结核病(RR-TB)。它能够有效缩短治疗周期并显著提高治疗效果，成为MDR/RR-TB患者的重要治疗选择。但是，某些患者在使用Bdq时会产生药物不良反应，上述药物反应始终是治疗过程中DR/RR-TB患者的临床难点。本综述将深入探讨Bdq的作用机制、推荐剂量、药物相互作用，临床应用以及带来的一系列不良影响，旨在为临床医生提供更安全、有效的使用Bdq的参考，帮助优化治疗方案，降低不良反应的风险。
Bendaquinoline (Bdq) is a diarylquinoline anti-tuberculosis drug, mainly used to treat multidrug-resistant tuberculosis (MDR-TB) or rifampicin-resistant tuberculosis (RR-TB). It can effectively shorten the treatment cycle and significantly improve the treatment effect, becoming an important treatment choice for MDR/RR-TB patients. However, some patients may experience adverse drug reactions when using Bdq, which remains a clinical challenge for DR/RR-TB patients during the treatment process. This review will delve into the mechanism of action, recommended dosage, drug interactions, clinical applications, and a series of adverse effects of Bdq, aiming to provide clinical doctors with safer and more effective references for the use of Bdq, help optimize treatment plans, and reduce the risk of adverse reactions.
| [1] | 朱艳丽. 耐药结核病的诊疗新进展[J]. 中国社区医师, 2022, 38(15): 6-8. |
| [2] | 朱青青. 耐多药/利福平耐药结核病防控中抗结核新药的使用及作用机制研究进展[C]//中国防痨协会, 重庆智飞生物制品股份有限公司. 中国防痨协会第33届全国学术大会暨中国防痨科技奖颁奖大会论文汇编. 2021: 216-221. |
| [3] | 胡鑫洋, 高静韬. 世界卫生组织《2024年全球结核病报告》解读[J]. 结核与肺部疾病杂, 2024, 5(6): 500-504. |
| [4] | 裴异, 陈检才, 封文军, 等. 含贝达喹啉方案治疗耐多药/广泛耐药结核病中期疗效前瞻性队列研究[J]. 中国感染控制杂, 2021, 20(12): 1102-1108. |
| [5] | Diacon, A.H., Pym, A., Grobusch, M.P., de los Rios, J.M., Gotuzzo, E., Vasilyeva, I., et al. (2014) Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline. New England Journal of Medicine, 371, 723-732. https://doi.org/10.1056/nejmoa1313865 |
| [6] | Field, S.K. (2015) Bedaquiline for the Treatment of Multidrug-Resistant Tuberculosis: Great Promise or Disappointment? Therapeutic Advances in Chronic Disease, 6, 170-184. https://doi.org/10.1177/2040622315582325 |
| [7] | Hicks, D.B., Liu, J., Fujisawa, M. and Krulwich, T.A. (2010) F1F0-ATP Synthases of Alkaliphilic Bacteria: Lessons from Their Adaptations. Biochimica et Biophysica Acta (BBA)—Bioenergetics, 1797, 1362-1377. https://doi.org/10.1016/j.bbabio.2010.02.028 |
| [8] | Rustomjee, R., Diacon, A.H., Allen, J., Venter, A., Reddy, C., Patientia, R.F., et al. (2008) Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary Tuberculosis. Antimicrobial Agents and Chemotherapy, 52, 2831-2835. https://doi.org/10.1128/aac.01204-07 |
| [9] | 肖和平. 耐药结核病化学治疗指南(2019年简版) [J]. 中国防痨杂志, 2019, 41(10): 1025-1073 |
| [10] | 胡春梅, 方刚, 张向荣, 等. 贝达喹啉联合常规抗结核药物治疗耐多药肺结核患者的长期疗效及安全性观察[J]. 国际医药卫生导报, 2018, 24(5): 711-715. |
| [11] | Makarov, V., Lechartier, B., Zhang, M., Neres, J., van der Sar, A.M., Raadsen, S.A., et al. (2014) Towards a New Combination Therapy for Tuberculosis with Next Generation Benzothiazinones. EMBO Molecular Medicine, 6, 372-383. https://doi.org/10.1002/emmm.201303575 |
| [12] | Wallis, R.S., Jakubiec, W., Mitton-Fry, M., Ladutko, L., Campbell, S., Paige, D., et al. (2012) Rapid Evaluation in Whole Blood Culture of Regimens for XDR-TB Containing PNU-100480 (Sutezolid), TMC207, PA-824, SQ109, and Pyrazinamide. PLOS ONE, 7, e30479. https://doi.org/10.1371/journal.pone.0030479 |
| [13] | Pym, A.S., Diacon, A.H., Tang, S., Conradie, F., Danilovits, M., Chuchottaworn, C., et al. (2015) Bedaquiline in the Treatment of Multidrug-and Extensively Drug-Resistant Tuberculosis. European Respiratory Journal, 47, 564-574. https://doi.org/10.1183/13993003.00724-2015 |
| [14] | Svensson, E.M., Dooley, K.E. and Karlsson, M.O. (2014) Impact of Lopinavir-Ritonavir or Nevirapine on Bedaquiline Exposures and Potential Implications for Patients with Tuberculosis-HIV Coinfection. Antimicrobial Agents and Chemotherapy, 58, 6406-6412. https://doi.org/10.1128/aac.03246-14 |
| [15] | Pandie, M., Wiesner, L., McIlleron, H., Hughes, J., Siwendu, S., Conradie, F., et al. (2016) Drug-Drug Interactions between Bedaquiline and the Antiretrovirals Lopinavir/Ritonavir and Nevirapine in HIV-Infected Patients with Drug-Resistant Tb. Journal of Antimicrobial Chemotherapy, 71, 1037-1040. https://doi.org/10.1093/jac/dkv447 |
| [16] | Ahmad, N., Ahuja, S.D., Akkerman, O.W., et al. (2018) Treatment Correlates of Successful Outcomes in Pulmonary Multi-Drug-Resistant Tuberculosis: An Individual Patient Data Meta-Analysis. Lancet, 392, 821-834. |
| [17] | World Health Organization (2020) Global Tuberculosis Report 2020. World Health Organization. |
| [18] | World Health Organization (2018) Global Tuberculosis Report 2018. World Health Organization. |
| [19] | World Health Organization (2019) Global Tuberculosis Report 2019. World Health Organization. |
| [20] | Lee, A., Xie, Y.L., Barry, C.E. and Chen, R.Y. (2020) Current and Future Treatments for Tuberculosis. BMJ, 368, m216. https://doi.org/10.1136/bmj.m216 |
| [21] | 李勇. 含贝达喹啉方案治疗耐多药结核病的研究进展[J]. 首都食品与医药, 2023, 30(10): 22-24. |
| [22] | 张玉霞, 熊瑜, 常婷婷, 等. 含贝达喹啉方案治疗耐药肺结核的不良反应分析[J]. 中国防痨杂志, 2022, 44(3): 239-245. |
| [23] | Wu, H., Tian, Y., Wang, X., Sun, J., Fan, L., Chen, M., et al. (2021) Twenty‐Four‐Week Interim Outcomes of Bedaquiline‐Containing Regimens in Treatment of Adolescents with Rifampicin‐Resistant Tuberculosis: A Retrospective Cohort Study in China. Journal of Paediatrics and Child Health, 58, 116-121. https://doi.org/10.1111/jpc.15672 |
| [24] | 杨松, 严晓峰, 唐神结, 等. 贝达喹啉临床应用研究进展[J]. 中华临床感染病杂志, 2022, 15(2): 152-160. |
| [25] | 赵珊, 耿建, 高春景. 耐多药肺结核患者临床治疗中应用含贝达喹啉联合治疗方案的效果分析[J]. 中外医疗, 2023, 42(7): 144-148. |
| [26] | Kim, C.T., Kim, T., Shin, H., Ko, Y.C., Hun Choe, Y., Kim, H., et al. (2018) Bedaquiline and Delamanid for the Treatment of Multidrug-Resistant Tuberculosis: A Multicentre Cohort Study in Korea. European Respiratory Journal, 51, Article ID: 1702467. https://doi.org/10.1183/13993003.02467-2017 |
| [27] | Shim, T.S., Pai, H., Mok, J., Lee, S.H., Kwon, Y., Choi, J.C., et al. (2023) A Prospective Patient Registry to Monitor Safety, Effectiveness, and Utilisation of Bedaquiline in Patients with Multidrug-Resistant Tuberculosis in South Korea. BMC Infectious Diseases, 23, Article No. 15. https://doi.org/10.1186/s12879-022-07955-6 |
| [28] | Pontali, E., Sotgiu, G., Tiberi, S., D'Ambrosio, L., Centis, R. and Migliori, G.B. (2017) Cardiac Safety of Bedaquiline: A Systematic and Critical Analysis of the Evidence. European Respiratory Journal, 50, Article ID: 1701462. https://doi.org/10.1183/13993003.01462-2017 |
| [29] | Conradie, F., Bagdasaryan, T.R., Borisov, S., Howell, P., Mikiashvili, L., Ngubane, N., et al. (2022) Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis. New England Journal of Medicine, 387, 810-823. https://doi.org/10.1056/nejmoa2119430 |
| [30] | World Health Organization (2017) Report of the Guideline Development Group Meeting on the use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis. World Health Organization. |
| [31] | 谢莉, 高静韬, 马丽萍, 等. 含贝达喹啉方案治疗耐多药肺结核对患者心电图QT间期的影响[J]. 中国防痨杂志, 2020, 42(7): 687-694. |
| [32] | 万荣, 李光妹, 季永静, 等. 含贝达喹啉耐药结核治疗方案对患者心电图QT间期的影响[J]. 临床荟萃, 2024, 39(7): 630-634. |
